0620/24SCR019-18/R10
Media Highlights
From the 2024 ASCO® Annual Meeting
8
Media Outlet Article / Coverage
Patient Power ASCO 2024: Why Lung Cancer Research Earned Big
Applause
Pharma Phorum ASCO: AstraZeneca's Triple Whammy in Lung And Breast Cancer
Pharmacy Times Osimertinib New Standard of Care for Stage 3, EGFRm
NSCLC
PharmaExec.com Phase III Trial Data Presented at ASCO Show Imfinzi
Improves Survival in Limited-Stage Small Cell Lung Cancer
Precision Medicine Online Pfizer's Lorbrena Produces Longest Progression-Free
Survival Seen in ALK-Positive NSCLC Patients
Precision Medicine Online Tagrisso Poised to Become Standard of Care in
Unresectable Stage III EGFR-Mutated NSCLC
STAT News AstraZeneca's Tagrisso Greatly Slows Cancer for Some
People with Stage 3 Lung Cancer
Targeted Oncology CROWN Trial of Lorlatinib Offers Durable PFS in ALK+ Lung
Cancer
The ASCO Post Consolidation Therapy With Durvalumab for Limited-Stage
SCLC
The ASCO Post Osimertinib for Patients With Locally Advanced EGFR-
Mutated NSCLC: A New Standard of Care?
The ASCO Post Osimertinib for Patients With Locally Advanced EGFR-
Mutated NSCLC: A New Standard of Care?
The ASCO Post Narjust Florez, MD, and David R. Spigel, MD, on Limited-
Stage Small Cell Lung Cancer: Results From the ADRIATIC
Study
The Guardian Trial Results for New Lung Cancer Drug Are 'off The Charts',
Say Doctors
The Pharma Letter Tagrisso Tops Triple-Dose of AstraZeneca ASCO Data
The Wall Street Journal Lung Cancer Was a Death Sentence. Now Drugs Are Saving
Lives.
Yahoo! News Incurable Lung Cancer Could Be 'Stopped In Its Tracks' by
New Pill
David Spigel, MD
SCRI
